No Baseline Dilated Eye Exam Required for Pre-Diabetes Patients Starting GLP-1 RAs
Patients with pre-diabetes do not need a baseline dilated eye examination before initiating GLP-1 receptor agonist therapy. The current ADA guidelines explicitly recommend baseline eye exams only for patients with established diabetes—not pre-diabetes 1.
Rationale Based on Guidelines
The 2025 ADA Standards of Care clearly delineate screening requirements:
- Type 2 diabetes: Initial dilated eye exam at the time of diagnosis 1
- Type 1 diabetes: Initial exam within 5 years after onset 1
- Pre-diabetes: No screening recommendation exists
The guidelines note that retinopathy takes at least 5 years to develop after the onset of hyperglycemia 1. Since pre-diabetes represents a state before frank hyperglycemia develops, the risk of existing retinopathy is negligible.
GLP-1 RA-Specific Considerations
While the guidelines emphasize that "retinopathy status should be assessed when glucose-lowering therapies are intensified, such as those using GLP-1 RAs, since rapid reductions in A1C can be associated with initial worsening of retinopathy" 1, this concern applies specifically to patients with established diabetes and existing retinopathy—not pre-diabetes patients.
The mechanism of concern involves rapid A1C reduction in patients who already have diabetic retinopathy 1. Pre-diabetes patients:
- Have no existing diabetic retinopathy to worsen
- Will not experience the rapid, dramatic A1C reductions seen in poorly controlled diabetes
- Lack the chronic hyperglycemic exposure that creates retinopathy risk
Recent Expert Consensus
A 2025 multi-disciplinary Delphi consensus specifically addressed this issue, recommending screening before GLP-1 RA initiation primarily for high-risk populations: >10 years diabetes duration and/or poor glucose control (HbA1c >10% or 86 mmol/mol) 2. Pre-diabetes patients meet neither criterion.
Clinical Algorithm
Do NOT obtain baseline eye exam if:
- Patient has pre-diabetes only (not diabetes)
- No prior diabetes diagnosis
- Starting GLP-1 RA for weight management or cardiovascular risk reduction
DO obtain baseline eye exam if:
- Patient has established type 2 diabetes (regardless of duration)
- Patient has type 1 diabetes >5 years duration
- Patient has known or suspected retinopathy
- Patient has diabetes >10 years or HbA1c >10% 2
Important Caveat
If a pre-diabetes patient has other ocular risk factors unrelated to diabetes (e.g., history of NAION in one eye, severe hypertension, significant cardiovascular disease), discuss potential ocular risks as part of shared decision-making 2, but this is distinct from requiring routine diabetic retinopathy screening.